IOVANCE BIOTHERAPEUTICS, INC. Financials Iovance Biotherapeutics, Inc.
Equities
IOVA
US4622601007
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.82 USD | -1.90% |
|
-5.43% | +20.05% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,493 | 6,806 | 2,995 | 1,009 | 2,081 | 2,801 | - | - |
| Enterprise Value (EV) 1 | 3,181 | 6,177 | 2,492 | 531.3 | 1,735 | 2,729 | 2,657 | 2,597 |
| P/E ratio | -17.4 x | -24.7 x | -8.56 x | -2.57 x | -4.3 x | -7.67 x | -14.7 x | 105 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 1,750 x | 18.3 x | 6.54 x | 3.62 x |
| EV / Revenue | - | - | - | - | 1,459 x | 17.9 x | 6.21 x | 3.36 x |
| EV / EBITDA | - | -23.7 x | -7.34 x | -1.36 x | -3.86 x | -7.3 x | -14.3 x | -11.1 x |
| EV / FCF | -19.2 x | -24.5 x | -9.38 x | -1.7 x | -4.52 x | -9.07 x | -19.2 x | 26.2 x |
| FCF Yield | -5.21% | -4.08% | -10.7% | -58.9% | -22.1% | -11% | -5.2% | 3.81% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 126,195 | 146,687 | 156,899 | 157,841 | 255,918 | 279,833 | - | - |
| Reference price 2 | 27.68 | 46.40 | 19.09 | 6.390 | 8.130 | 10.01 | 10.01 | 10.01 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 1.189 | 152.8 | 428.1 | 773.2 |
| EBITDA 1 | - | -260.8 | -339.6 | -389.6 | -449 | -373.6 | -185.5 | -233.9 |
| EBIT 1 | -206.9 | -261.9 | -342.7 | -398.9 | -460.6 | -371.5 | -219.5 | -0.4658 |
| Operating Margin | - | - | - | - | -38,734.99% | -243.2% | -51.28% | -0.06% |
| Earnings before Tax (EBT) 1 | -197.6 | -259.6 | -342.3 | -395.9 | -447.5 | -356.6 | -199 | 13.95 |
| Net income 1 | -197.6 | -259.6 | -342.3 | -395.9 | -444 | -356.3 | -199 | 11.27 |
| Net margin | - | - | - | - | -37,345.42% | -233.23% | -46.49% | 1.46% |
| EPS 2 | -1.590 | -1.880 | -2.230 | -2.490 | -1.890 | -1.305 | -0.6820 | 0.0957 |
| Free Cash Flow 1 | -165.8 | -251.9 | -265.5 | -313.2 | -384.1 | -301 | -138.2 | 99 |
| FCF margin | - | - | - | - | -32,305.3% | -197.05% | -32.3% | 12.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 878.67% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.238 | 0.469 | 0.482 | 0.715 | 30.77 | 61.17 | 78.21 | 89.29 | 102.6 |
| EBITDA 1 | -98.12 | -89.92 | -97.49 | -97.94 | -104.2 | -108.1 | -107.2 | - | - | - | -122.1 | -128.9 | -138.5 | - | - |
| EBIT 1 | -99.46 | -91.71 | -99.73 | -100.4 | -107 | -110.9 | -110.1 | -118.4 | -121.3 | -117.7 | -98.2 | -79.33 | -73.4 | -71.98 | -65.39 |
| Operating Margin | - | - | - | - | - | - | -46,254.62% | -25,236.89% | -25,156.85% | -16,464.62% | -319.17% | -129.7% | -93.84% | -80.61% | -63.71% |
| Earnings before Tax (EBT) 1 | -99.33 | -91.61 | -99.35 | -99.62 | -105.3 | -107.4 | -107 | -115 | -118.1 | -114.4 | -92.97 | -74.93 | -72.1 | -70.9 | -64.43 |
| Net income 1 | -99.33 | -91.61 | -99.35 | -99.62 | -105.3 | -107.4 | -106.5 | -113.8 | -116.4 | -113 | -92.98 | -74.96 | -72.2 | -70.9 | -64.43 |
| Net margin | - | - | - | - | - | - | -44,759.66% | -24,255.86% | -24,145.02% | -15,800.84% | -302.21% | -122.55% | -92.32% | -79.4% | -62.77% |
| EPS 2 | -0.6300 | -0.5800 | -0.6300 | -0.6300 | -0.6400 | -0.5000 | -0.4700 | -0.4600 | -0.4500 | -0.4200 | -0.3470 | -0.2750 | -0.2600 | -0.1975 | -0.1725 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 313 | 629 | 503 | 477 | 345 | 72.4 | 144 | 204 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -166 | -252 | -266 | -313 | -384 | -301 | -138 | 99 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.92 | 46.8 | 37.6 | 20.4 | 22.3 | 11.6 | 19.3 | 19.3 |
| Capex / Sales | - | - | - | - | 1,874.68% | 7.56% | 4.52% | 2.5% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
10.01
USD
Average target price
25.92
USD
Spread / Average Target
+158.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.12% | 2.8B | |
| -32.63% | 9.2B | |
| -5.66% | 3.12B | |
| -17.75% | 2.07B | |
| -24.39% | 1.59B | |
| +65.65% | 1.44B | |
| +32.83% | 830M | |
| -6.55% | 724M | |
| -29.80% | 507M | |
| -7.36% | 275M |
- Stock Market
- Equities
- IOVA Stock
- Financials Iovance Biotherapeutics, Inc.
